Apoptosis Regulator BAX drugs in development by Therapy Areas, Indications, Stages, MoA, RoA, Molecule Type, and Key Players, 2023

The report also covers products from therapy areas such as Central Nervous System, Oncology, Cardiovascular, and Ophthalmology which include the indications Amyotrophic Lateral Sclerosis, Neurodegenerative Diseases, Lung Cancer, Melanoma, Myocardial Infarction, Acute Ischemic Stroke, and Ophthalmology. It also reviews key players involved in Apoptosis Regulator BAX targeted therapeutics development with respective active and dormant or discontinued products.

The Apoptosis Regulator BAX pipeline targets constitutes close to ten molecules. Out of which, approximately five molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Filing rejected/ Withdrawn, Phase II, Preclinical, and Discovery stages are 1, 1, 2, and 1 respectively. Similarly, the universities portfolio in Preclinical, and Discovery comprises 2, and 3 molecule.

Apoptosis Regulator BAX overview

Apoptosis regulator BAX or bcl-2-like protein 4 is a protein is encoded by the BAX gene. It accelerates programmed cell death by antagonizing the apoptosis repressor BCL2. It promotes activation of CASP3, and thereby apoptosis. It undergoes a conformation change that causes translocation to the mitochondrion membrane, leading to the release of cytochrome c that then triggers apoptosis under stress conditions.

For a complete picture of Apoptosis Regulator BAX’s drug pipeline, buy the report here.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.

Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.